Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
Mersana Therapeutics, a clinical-stage biopharmaceutical company, will report its Q4 and full-year financial results on February 28, 2024. The company focuses on developing antibody-drug conjugates for cancer treatment.
02/21/2024 - 08:00 AM
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 877-270-2148 (domestic) or 412-902-6510 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com , and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com .
Contact: Jason Fredette 617-498-0020jason.fredette@mersana.com
When will Mersana Therapeutics report its financial results for Q4 and full year 2023?
Mersana Therapeutics will report its financial results for the fourth quarter and full year ended December 31, 2023, on Wednesday, February 28, 2024.
What does Mersana Therapeutics focus on in terms of drug development?
Mersana Therapeutics focuses on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need.
How can investors access the conference call and webcast for Mersana Therapeutics?
Investors can access the conference call and webcast by dialing 877-270-2148 (domestic) or 412-902-6510 (international). A live webcast will also be available on the Investors & Media section of the Mersana website at www.mersana.com.
MRSN Rankings
#5398 Ranked by Stock Gains
MRSN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About MRSN
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.